Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AUSTIN, Texas, Feb. 23, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in BTIG’s 2018 Healthcare Conference from February 28, 2018 through March 1, 2018 in Snowbird, Utah. BTIG’s annual conference will bring together more than 100 leading healthcare companies with institutional investor clients.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 550 employees, BTIG, LLC and its affiliates operate out of 17 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors LLC
Tel 212-915-2568
[email protected]
